Matthias Frei

Dr. Matthias Frei


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MFMatthias Frei
Matthias Frei
TWThomas Wein
Thomas Wein
Franz BracherFranz Bracher
Franz Bracher
Sirtuins are involved in cellular processes in multiple ways. Therefore, the development of potent and selective Sirt2 inhibitors provides an important contribution to understanding physiological and pathophysiological mechanisms, particularly for the research and treatment of cancer and neurodegenerative diseases. Based on established SirReal-type lead inhibitors, further selective Sirt2 inhibitors were synthesized in a docking-guided rigidization approach, and the knowledge regarding requirements and properties of the Sirt2-binding pocket was expanded by means of a comprehensive SAR study. Naphthalene derivative FM69 emerged from the screening as the most potent rigidized inhibitor, which, with an IC50 value of 0.15 µM against Sirt2, represents a promising foundation for the further development of novel potent and selective Sirt2 inhibitors based on the presented rigidization strategy.

19 August 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
RWRicky Wirawan
Ricky Wirawan
MFMatthias Frei
Matthias Frei
AHAnna Heider
Anna Heider
NPNiklas Papenkordt
Niklas Papenkordt
FFFlorian Friedrich
Florian Friedrich
Franz BracherFranz Bracher
Franz Bracher
The duality of halogen-bonding-mediated ligand stabilization and the inteference of NAD + co-factor binding represents an effective strategy in the development of highly potent SIRT2 inhibitors.

Verified
Journal Article
Open access
PDF file
MFMatthias Frei
Matthias Frei
RWRicky Wirawan
Ricky Wirawan
TWThomas Wein
Thomas Wein
Franz BracherFranz Bracher
Franz Bracher
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic strategy for the treatment of currently incurable diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis. Guided by molecular docking and MM/GBSA validation studies, a lead structure-based hybridization strategy was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93, we present a highly potent and subtype selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and contributes to the extension of the current SAR profile. The structural modification strategy employed in this study proved to be highly promising, resulting in the identification of the most potent low-molecular-weight Sirt2 inhibitor reported to date, providing a promising target for further medicinal chemistry-driven SAR studies.

12 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MFMatthias Frei
Matthias Frei
RWRicky Wirawan
Ricky Wirawan
TWThomas Wein
Thomas Wein
Franz BracherFranz Bracher
Franz Bracher
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic approach for the treatment of hitherto incurable diseases such as Parkinson's disease, Huntington’s disease, Alzheimer's disease and multiple sclerosis. Guided by docking studies, a lead structure-based hybridization concept was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93 we present a highly potent and selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and extends current structure-activity relationships. The structural modification strategy employed in this study proved to be a highly promising approach, resulting in the identification of the most potent low-molecular Sirt2 inhibitors reported to date.